IL2 and cancer: Interferon and high dose IL-2 are the earliest immunotherapies clinically used to treat various malignant tumors, whereas new cancer immunotherapies have emerged in the past decade, such as the above-mentioned immune checkpoint inhibitors that activate quiescent T cells and impair the ability of tumors to turn off activated T cells in the tumor microenvironment.